FRAMINGHAM, Mass., September 21, 2016 – Alzheon Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that the company will present at these upcoming investor conferences:
- Ladenburg Thalmann 2016 Healthcare Conference: Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon, will present a company overview on Tuesday, September 27, 2016, at 9:00 a.m. ET at the Sofitel in New York, NY.
- BIO Investor Forum 2016: Aidan Power, MB, BCh, MSc, MRCPsych, Vice President of Program and Portfolio Management of Alzheon, will participate on a panel, “Benefiting from Innovative Clinical Trial Designs: Biomarkers, Patient-Oriented Endpoints, Batch Trials, and Digital Tools,” on Wednesday, October 19, 2016, at 11:00 a.m. PT at the Westin St. Francis Hotel in San Francisco, CA.
About Alzheon
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been tested in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform is focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.
Media Contact:
Kathryn Morris
The Yates Network
Tel: 845‐635‐9828
kathryn@theyatesnetwork.com